carbidopa + levodopa


United Lab


Concise Prescribing Info
Per 100 mg/25 mg tab Levodopa 100 mg, carbidopa 25 mg. Per 250 mg/25 mg tab Levodopa 250 mg, carbidopa 25 mg
Dosage/Direction for Use
100 mg/25 mg tid. May be increased by 1 tab daily or every other day. Max: 2 g/200 mg. Maintenance: Individualized dosage. At least 70-100 mg carbidopa/day. When more levodopa is required, 250 mg/25 mg should be substituted at a dosage of 1 tab tid or qid. If necessary, 250 mg/25 mg may be increased by ½-1 tab every other day to a max of 8 tab/day. Patient receiving levodopa Discontinue levodopa at least 12 hr before therapy. Levodopa + carbidopa should be given as the 1st morning dose after a night w/o any levodopa. Dose should be approx 20% of the previous levodopa daily dose. Levodopa requirement >1,500 mg/day: 1 tab (250 mg/25 mg) tid-qid. Levodopa requirement <1,500 mg/day: 1 tab (100 mg/25 mg) tid-qid. Patient receiving levodopa w/ another decarboxylase inhibitor combination Discontinue levodopa at least 12 hr before starting therapy. Start w/ the same amount of levodopa as w/ another levodopa + decarboxylase inhibitor. Patient receiving other antiparkinsonian agent Dose adjustment may be necessary.
Should be taken on an empty stomach: May be taken w/ meals if GI discomfort occurs.
Hypersensitivity. Concomitant use w/ MAOIs, selegiline HCl, sympathomimetic amine (eg, epinephrine, norepinephrine or isoproterenol). Clinical or laboratory evidence of uncompensated CV, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma) or renal disease. Narrow angle glaucoma, sympathomimetic amine administration (eg, epinephrine, norepinephrine or isoproterenol), severe psychoses, suspicious undiagnosed skin lesions or history of melanoma (since levodopa may activate a malignant melanoma).
Special Precautions
Not for the treatment of medicine-induced extrapyramidal reactions. History of MI w/ residual atrial, nodal or ventricular arrhythmia; dyskinesia, hallucinations; patients w/ previous or current psychoses; chronic wide-angle glaucoma. Neuroleptic malignant syndrome (NMS) or NMS-like symptom; avoid abrupt w/drawal or reduction. History of seizures, conditions associated w/ seizure or lowered seizure threshold. Require periodic evaluation of hepatic, hematopoietic, CV & renal function. Long-term use. Dark color (red, brown/black) may appear in saliva, urine or sweat or may discolor garments. Elevated liver function tests, abnormal BUN & +ve Coombs' test. False +ve result for ketonuria determination in urine & false -ve result w/ glucose-oxidase test for glucosuria. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Asthenia, fatigue, malaise, sense of stimulation. Orthostatic hypotension; anorexia; nausea, vomiting; involuntary movements, intermittent myoclonic body jerks during sleep; dyskinesia, dream abnormalities eg, nightmares, insomnia, drowsiness; blepharospasm.
Drug Interactions
Absorption may be affected w/ anticholinergics. Symptomatic postural hypotension w/ antihypertensives & severe orthostatic hypotension w/ selegiline. HTN & dyskinesia may occur w/ TCAs. Reduced therapeutic effect w/ dopamine D2 receptor antagonists eg, phenothiazine, butyrophenones, risperidone & INH. Dopamine-depleting agents eg, reserpine & tetrabenazone; other drugs depleting monoamine stores; vit B6. Loss of therapeutic response w/ phenytoin & papaverine. Increased (w/ metoclopramide) & decreased (w/ Fe sulfate/gluconate) bioavailability. Impaired absorption w/ amino acids.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BA02 - levodopa and decarboxylase inhibitor ; Belongs to the class of dopa and dopa derivative dopaminergic agents. Used in the management of Parkinson's disease.
Lavida 100 mg/25 mg tab
30's (P675/box, P22.5/tab)
Lavida 250 mg/25 mg tab
30's (P1,072.5/box, P35.75/tab)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in